Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-597-5 | CAS number: 97-63-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Gene mutations in bacteria: An EMA study is reliable, but lacks one standard strain. Corresponding studies for MMA and nBMA are complete – and equally negative. Based on the common mode of action, the Albertini review (2017), the category data and the comprehensive methacrylate overview it is evident, that an additional bacterial reverse mutation test is not necessary. EMA is regarded as non-mutagenic in bacteria. This conclusion, partly based on category read-across, is taken with high confidence.
Gene mutations in mammalian cells: An EMA study is reliable with significant restrictions (no data with metabolic activation). Increased mutation rates, also in the read-across chemical MMA correlate with small colony mutants and chromosome aberrations. Tests in the more robust HPRT test are negative in summary. With the corresponding studies for MMA and nBMA the dataset is complete. Based on the common mode of action, the Albertini review and the category data, it is evident, that an additional gene mutation test in mammalian cells is not necessary. Regarding gene mutations, EMA is regarded as non-mutagenic in mammalian cells. Positive findings are related to chromosome breakage. This conclusion, partly based on category read-across, is taken with high confidence.
Chromosome mutations in mammalian cells: The EMA key study is negative, but a supporting study is positive. Throughout the lower alkyl methacrylate category, positive findings in chromosome aberration tests are associated with high toxicity and very high concentrations (above the current guideline recommendation. Performed under currently prevalent test conditions, practically all of these tests – at correspondingly lower concentrations - would lead to a negative test result today. Based on the common mode of action, the Albertini review , the category data and the comprehensive methacrylate overview, it is evident, that an additional chromosome mutation test in mammalian cells is not necessary. Regarding gene mutations, EMA is regarded as non-mutagenic in mammalian cells. This conclusion, partly based on category read-across, is taken with high confidence and it is consistent with the result of a RAC discussion regarding MMA in 2016, based on almost the same database.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Remarks:
- The study was conducted in accordance with a recognized international scientific procedure and followed the test protocol and procedures of Ames (1975). Complete study results were presented supporting the conclusions that ethyl methacrylate was not mutagenic in this test system. Full description of the test material was provided.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Qualifier:
- according to guideline
- Guideline:
- other: Ames et al. (1975)
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Metabolic activation system:
- The S-9 fractions of Aroclor 1254-induced, male Sprague-Dawley rats and male Syrian Hamster livers were prepared immediately prior to use. The S-9 mixes contained 10% S-9.
- Test concentrations with justification for top dose:
- 100-10000 µg/plate
- Negative solvent / vehicle controls:
- yes
- Remarks:
- ethanol (95%)
- Positive controls:
- yes
- Remarks:
- Metabolic activation (S9): 2-Aminoanthracene: with all strains No Metabolic activation: Sodium azide: TA100 and TA1535 4-Nitro-o-phenylenediamine: TA98 9-Aminoacridine: TA1537
- Details on test system and experimental conditions:
- TEST PERFORMANCE: The test followed a pre-incubation protocol. The test material, Salmonella culture, and S-9 mix or buffer were incubated at 37 degrees C, without shaking, for 20 minutes. The top agar was added, and the contents of the tubes mixed and poured onto the surface of Vogel-Bonner medium in a petri dish. The histidine-revertant colonies on these plates were counted after 2 days of incubation at 37 degrees C.
A preliminary cytotoxicity assays was conducted using TA100 to determine the appropriate dose range. Once determined, the test doses were performed in triplicate, repeated one week following the initial trial.
A maximum of 0.5 ml of solvent was added to each plate. Concurrent solvent and positive controls in the presence or absence of S-9 were performed. - Evaluation criteria:
- A positive response was demonstrated when a reproducible dose-related increase over the corresponding solvent control was seen, and it was judged weakly positive if a low-level dose response was seen.
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Conclusions:
- In a reliable published study, the test substance was negative in a bacterial reverse mutation assay.
- Executive summary:
In a reliable published study, the test substance was negative in a bacterial reverse mutation assay.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- Method and results sufficient described, similar to OECD-guideline 476.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Principles of method if other than guideline:
- In addition to the mutation test at the TK locus, analyses for chromosomal aberrations and induction of micronuclei in vitro were run.
- GLP compliance:
- not specified
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- TK
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- heterozygous TK+/- (maintained according to Clive and Spector, 1975)
Properly maintained: yes
Periodically checked for mycoplasm: yes, every 4 weeks
LOCUS EXAMINED: Thymidine kinase (TK), using TFT (triflourthymidine, 1 μg/ml) - Metabolic activation:
- without
- Test concentrations with justification for top dose:
- Cytogenicity assay: 900-2100 µg/mL
Genotoxicity assays: 700-2100 μg/mL; 1692-2298 μg/mL
In the first experiment there were 19 doses and a control used: ranging from 700 to 2100 μg/mL. In a second experiment conducted concurrent with this, there were 28 doses ranging from 1692 to 2298 ug/mL. - Vehicle / solvent:
- DMSO
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- methylmethanesulfonate
- Details on test system and experimental conditions:
- Fischer's powered or liquid Medium for Leukemic Cells of Mice supplemented with sodium pyruvate, plunoric, penicillin, streptomycin, and horse serum was used.
TEST PERFORMANCE: L5178Y/TK+/- cells were treated without exogenous activation fo 4 hr according to procedures described by Clive et al. 1979. Cells were centrifuged, washed twice with fresh medium, resuspended in fresh medium and incubated on a roller drum at 37 degrees C, to obtain a log-phase growth for 2 days. They were then cloned with TFT selection (1 μg/ml) and without selection in BBL agar (0.22 %)-supplemented colony medium. Following cell treatment and wash, 10 μM BrdUrd was added to the cultures used in the cytogenetic assay. Cells were incubated for 14 hrs and Colcemid (0.1 μg/ml) added for the last 2 hours. Cells were treated with hypotonic KCL and fixed in acetic acid : methanol (1:3). Slides
were prepared, stained using flourescense-plus-Giemsa method. 200 metaphase spreads were
analyzed for abberations for each dose. Chromatid and chromosome gaps were recorded but not included as aberrations. - Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Positive controls validity:
- valid
- Additional information on results:
- Methyl methacrylate produced a positive mutagenic response at the tk locus with responses variable at 2-4 times background but consistently positive at doses from 2300 to 3000 ug/ml. The highest mutant frequency occurred at 2800 ug/ml with 298 mutants/10E6 survivors. Because the background frequency was relatively high after the analysis of 100 metaphases, an additional 100 metaphases were scored. Weak positives were recorded at 2200, 2500, 2700, 2800 and 3000 ug/ml. The highest response was at 2800 ug/ml with 45 aberrations in 39 of 200 metaphases (background = 16 aberrations in 15 of 200 metaphases scored). It should be noted that the high background was due to an increase in the number of chromosome rearrangements and breaks in the control culture. No concurrent increase in background TK mutant or micronucleus frequency was observed. The MMA treated cells showed a significant increase in chromatid events with no change in the number of chromosome events. Micronucleus responses were also variable with weak positive responses recorded at 2200, 2400, 2500, 2800, 2900 and 3000 ug/ml. The greatest response was at 2900 ug/ml with micronuclei in 25 of 1000 binucleates (background = 9 /1000). The 2 lowest doses, 1000 and 1750, were negative for mutagenicity, aberrations and micronuclei. All test concentrations, except the lowest, are above the guideline recommendation of 10 mM in OECD 476 (1000 µg/ml = 10 mM).
- Conclusions:
- Ethyl Methacrylate induced a weakly positive response that was non-linear. The authors concluded that this was probably due to induction of chromosomal events rather than point mutations.
- Executive summary:
In a reliable published study, methyl methacrylate induced a weakly positive response that was nonlinear. The authors concluded that this was probably due to induction of chromosomal events rather than point mutations.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- no repeat trial, limited data on cytotoxicity
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- GLP compliance:
- not specified
- Type of assay:
- in vitro mammalian chromosome aberration test
- Species / strain / cell type:
- other: Type of cell used: Chinese hamster ovary (CHO) cells
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 : Sprague-Dawley rat liver, induced with Aroclor 1254 (PCB)
- Test concentrations with justification for top dose:
- -S9 mix (continous exposure): 0, 1000, 1600, 3000 µg/ml +S9 mix (short time exposure):
0, 1000, 1600, 3000, 5000 µg/ml - Vehicle / solvent:
- DMSO
- Positive controls:
- yes
- Remarks:
- -S9 mix, Mitomycin C, 0.125 and 0.250 µg/ml +S9 mix, Cyclophosphamide, 5 and 7.5 µg/ml
- Details on test system and experimental conditions:
- Cultures/test concentration : 2
Cultures with metabolic activation were treated for 2 h in culture medium (McCoy's 5A) without serum. At the end of the treatment period the medium was exchanged to medium without test material. Cultures without metabolic activation were treated until colcemid was added. For mitotic arrest colcemid was added 2-2.5 h before harvest. The cultures were harvested after a culture time of 12 h (with S9 13 h) after the start of treatment. 2x100 metaphases were scored for each test concentration.The test was performed in a single trial (no repeat). - Species / strain:
- Chinese hamster Ovary (CHO)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- other: 5000 µg/ml were cytotoxic with metabolic activation. Other than that, no details on cytotoxicity were reported.
- Conclusions:
- Using a valid scientific method, the test substance did not induce structural chromosomal aberrations in CHO cells, with or without an exogenous metabolic activation system.
- Executive summary:
Using a valid scientific method, the test substance did not induce structural chromosomal aberrations in CHO cells, with or without an exogenous metabolic activation system.
Referenceopen allclose all
Comparison of results: Chromosome aberrations, micronucleus induction and mutations at the TK locus, small colony mutants and survival.
EMA [µg/ml] | Chromatid Breaks | Chromatid Rearrangements | Chromosome Breaks | Chromosome Rearrangements | Total No. aberrations | % Cells with aberrations |
0 | 3 | 0 | 4 | 2 | 9 | 8 |
900 | 4 | 2 | 10 | 7 | 23 | 18 |
1450 | 5 | 0 | 7 | 0 | 12 | 12 |
1550 | 1 | 1 | 3 | 6 | 11 | 11 |
1626 | 5 | 1 | 8 | 6 | 20 | 10 |
1676 | 2 | 0 | 7 | 2 | 11 | 10 |
1750 | 3 | 1 | 7 | 6 | 17 | 13 |
2100 | 5 | 1 | 4 | 5 | 15 | 14 |
Increases in any type of mutations correlate strongly with a decrease in survival. All test concentrations, except the lowest, are above the guideline recommendation of 10 mM in OECD 476 (1000 µg/ml = 10 mM). The increase in mutations at the TK locus is primarily due to small colony mutants with a trend to more small colonies at higher concentrations, indicating that these are primarily due to deletions (chromosome mutations) rather than gene mutations.
Mutagenicity of Ethyl Methacrylate
Experiment 1
Conc (µg/mL) | Survival (%) | Mutant frequency (mutants/ 10e6 survivors) |
0 | 100 | 61 |
700 | 71 | 72 |
900 | 48 | 78 |
1000 | 34 | 98 |
1100 | 46 | 93 |
1200 | 28 | 110 |
1300 | 28 | 106 |
1450 | 15 | 124* |
1500 | 19 | 123* |
1550 | 14 | 143* |
1600 | 9 | 165** |
1626 | 16 | 144* |
1650 | 9 | 116 |
1676 | 16 | 120 |
1700 | 6 | 175** |
1750 | 21 | 99 |
1800 | 2 | 251** |
1900 | 15 | 89 |
2000 | 5 | 134** |
Experiment 2
0 | 100 | 61 |
1692 | 13 | 144* |
1704 | 22 | 96 |
1716 | 31 | 114 |
1728 | 32 | 90 |
1740 | 37 | 95 |
1752 | 14 | 126* |
1764 | 32 | 97 |
1776 | 4 | 209** |
1788 | 7 | 203** |
1800 | 15 | 124* |
1812 | 2 | 198** |
1848 | 14 | 211* |
1860 | 15 | 121 |
1872 | 5 | 170** |
1884 | 24 | 104 |
1896 | 23 | 93 |
1908 | 16 | 151* |
1920 | 15 | 95 |
1932 | 17 | 138* |
1944 | 25 | 93 |
1956 | 22 | 103 |
1968 | 23 | 113 |
1980 | 33 | 114 |
1992 | 15 | 134* |
2004 | 18 | 110 |
2030 | 18 | 127* |
2148 | 8 | 219** |
2298 | 10 | 162* |
* positive response
** positive response, but less than 10% survival
This chemical did not induce structural chromosomal aberrations in CHO cells, with or without an exogenous metabolic activation system.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Description of key information
There are no in vivo data for EMA. However, reliable data are available from the category neighbours MMA and nBMA:
Hachiya et al. (1982) (other sources translate the name as Hachitani) reported on a negative bone marrow micronucleus assay with MMA in mice. In an acute test methyl methacrylate was given by gavage in doses ranging from 1,130 to 4,520 mg/kg, in a subacute assay daily doses of 1,130 mg/kg were given on 4 consecutive days. All groups consisted of 6 animals; sampling was done 24 h after (last) administration. There was no increase in the frequency of micronucleated polychromatic erythrocytes. The percentage of reticulocytes from all bone marrow cells was not affected data on general toxicity were not given.
N-BMA has been assessed in vivo in a mouse bone marrow micronucleus test (Cilliutti, 1999). The test substance has been dosed up to the highest guideline dose of 2000 mg/kg via the intraperitoneal route. No toxicity was seen at the low and medium doses (500 and 1000 mg/kg) while slight toxicity was demonstrated at the high dose by a slight reduction in the PCE/NCE coefficient. As no increase in micronuclei was observed, n-BMA is regarded as non-mutagenic under the test conditions.
Link to relevant study records
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- read-across based on grouping of substances (category approach)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- Similar to OECD-guideline 474, all relevant study details available
- Justification for type of information:
- Read across from the methacrylic metabolite donor substance
REPORTING FORMAT FOR THE ANALOGUE APPROACH
see attached category document
1. HYPOTHESIS FOR THE ANALOGUE APPROACH
see attached category document, chapter 1.1
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
see attached category document, chapter 1
3. ANALOGUE APPROACH JUSTIFICATION
see attached category document, chapter 5 (Toxikokinetics) and endpoint specific chapters
4. DATA MATRIX
see attached category document, endpoint specific chapters - Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- GLP compliance:
- not specified
- Type of assay:
- micronucleus assay
- Species:
- mouse
- Strain:
- other: ddy
- Sex:
- male
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil, 25 ml/kg
- Duration of treatment / exposure:
- 4 doses
- Frequency of treatment:
- 3 doses: once, 24 h before terminal sacrifice
1 dose: 4 split doses every 24 h, the last one 24 h before terminal sacrifice, total duration 5 d - Post exposure period:
- 24 h
- Dose / conc.:
- 25 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 130 mg/kg bw/day (nominal)
- Dose / conc.:
- 2 260 mg/kg bw/day (nominal)
- Dose / conc.:
- 4 520 mg/kg bw/day (nominal)
- Remarks:
- Doses corresponds to 50% of LD50
- Remarks:
- 4 x 1130 mg/kgbw per dose
- No. of animals per sex per dose:
- 6 (repeated treatment: 5)
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- 3 mg Mitomycin C, single dose by i.p. administration 24 h prior to preparation
- Tissues and cell types examined:
- Sampling time for bone marrow: 3 single doses - 24 h post-administration; for repeated administration: 5 days after first administration.
- Statistics:
- according to Kastenbaum/Bowman
- Sex:
- male
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Remarks:
- at all doses, single and repeated
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- Interpretation of results (migrated information): negative
The substance has been administered by gavage as a solution in olive oil in 3 single doses ranging from 1130 mg/kg to 4520 mg/kg (0.5 LD50) 24 h prior to preparation of the bone marrow. A separate group of 5 animals was administered 4 doses of 1130 mg/kg 96, 72, 48 and 24 h prior to preparation. Olive oil (25 ml/kg) was used as the solvent control and mitomycin C (3 mg/kg, i.p.) as the positive control. 2000 erythrocytes were evaluated per animal (12000/10000 per dose). No increase in micronucleated polychromatic erythrocytes was observed at any dose, while an induction of micronuclei was seen in the positive control. The substance has been administered by gavage as a solution in olive oil in 3 single doses ranging from 1130 mg/kg to 4520 mg/kg (0.5 LD50) 24 h prior to preparation of the bone marrow. A separate group of 5 animals was administered 4 doses of 1130 mg/kg 96, 72, 48 and 24 h prior to preparation. Olive oil (25 ml/kg) was used as the solvent control and mitomycin C (3 mg/kg, i.p.) as the positive control. 2000 erythrocytes were evaluated per animal (12000/10000 per dose). No increase in micronucleated polychromatic erythrocytes was observed at any dose, while an induction of micronuclei was seen in the positive control. MMA was not mutagenic in vivo under test conditions. - Executive summary:
The substance has been administered by gavage as a solution in olive oil in 3 single doses ranging from 1130 mg/kg to 4520 mg/kg (0.5 LD50) 24 h prior to preparation of the bone marrow. A separate group of 5 animals was administered 4 doses of 1130 mg/kg 96, 72, 48 and 24 h prior to preparation. MMA was not mutagenic in vivo under test conditions.
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- read-across based on grouping of substances (category approach)
- Adequacy of study:
- weight of evidence
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- Read across from analogous category member
REPORTING FORMAT FOR THE ANALOGUE APPROACH
see attached category document
1. HYPOTHESIS FOR THE ANALOGUE APPROACH
see attached category document, chapter 1.1
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
see attached category document, chapter 1
3. ANALOGUE APPROACH JUSTIFICATION
see attached category document, chapter 5 (Toxikokinetics) and endpoint specific chapters
4. DATA MATRIX
see attached category document, endpoint specific chapters - Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.5395 (In Vivo Mammalian Cytogenics Tests: Erythrocyte Micronucleus Assay)
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- micronucleus assay
- Species:
- mouse
- Strain:
- Swiss
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Nossan s.r.l., Corezzana, Italy,
- Age at study initiation: 5-6 weeks
- Weight at study initiation: 26-34 grams for males and 22-27 grams for females
- Assigned to test groups randomly: no data
- Housing: 5/polycarbonate cage, by sexes
- Diet (e.g. ad libitum): Altromin MT diet
- Water (e.g. ad libitum): tap water
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2
- Humidity (%): 55 +/- 10
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- intraperitoneal
- Vehicle:
- - Vehicle(s)/solvent(s) used: corn oil
- Justification for choice of solvent/vehicle: solubility
- Concentration of test material in vehicle: no data - Duration of treatment / exposure:
- Single administration
- Post exposure period:
- 24 and 48 hour sampling time
- Remarks:
- Doses / Concentrations:
0 (vehicle), 500, 1000 and 2000 mg/kg
Basis: - No. of animals per sex per dose:
- Each group consisted of five male and five female animals with the exception of the control and high-dose groups, which included an additional five animals of each sex per group.
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Mitomycin C
- Route of administration: intraperitoneal
- Doses / concentrations: 2.0 mg/kg bw - Tissues and cell types examined:
- 5 animals/sex/group were sacrificed at the 24-hour sampling time. The additional animals were sacrificed at the 48-hour sampling time. At least 2000 polychromatic cells per animal were examined for the presence of micronuclei. The ratio of mature to polychromatic erythrocytes was also determined.
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION:
A preliminary toxicity study was conducted in which groups of two male and two female mice were dosed once (i.p. injection) with n-butyl methacrylate at 2000, 1500 and 1000 mg/kg. Clinical signs were observed in all animals on the day of dosing, but all animals recovered by the following day. No bone marrow cytotoxicity, as measured by increases in the NCE/PCE ratio, was observed. The doses for the definitive study were selected based on this preliminary toxicity study.
TREATMENT AND SAMPLING TIMES ( in addition to information in specific fields):
Five animals per sex from each group were sacrificed at the 24 hour sampling time. The additional animals were sacrificed at the 48 hour sampling time.
DETAILS OF SLIDE PREPARATION:
The femurs were removed and bone marrow cells obtained by flushing with foetal calf serum. The cells were centrifuged and a concentrated suspension prepared to make smears on slides. These slides were air-dried and then stained with May-Gruenwald and Giemsa, and mounted with Eukitt. Three slides were made from each animal.
METHOD OF ANALYSIS:
The slides were randomly coded by a person not involved in the subsequent microscope scoring. The slides were examined under low power (x 16 objective) and one slide from each animal was selected according to staining and quality of smears. At least 2000 polychromatic cells per animal were examined for the presence of micronuclei at high power (x 100 objective, oil immersion). At the same time the numbers of normal and micronucleated normochromatic erythrocytes were also recorded. - Evaluation criteria:
- The test substance is considered to induce micronuclei if a statistically significant increase in the micronucleus incidence in polychromatic erythrocytes (at P<0.05) is observed in any treatment group, in the pooled data for both sexes, or for either sex considered separately.
- Statistics:
- Only counts obtained from polychromatic cells were subjected to statistical analysis. Using the original observations (and not the micronucleus frequencies per 1000 cells), a modified Chi-squared calculation was employed to compare treated and control groups. The degree of heterogeneity within each group was first calculated and where this was significant it was taken into account in the comparison between groups. Variance ratios or Chi-squared values are taken to show the significance of any difference between each treated group and the controls.
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Remarks:
- but tested up to the limit dose
- Vehicle controls validity:
- valid
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- No statistically significant increase in the incidence of micronucleated PCE's over the control value was observed at any dose-level. Slight increases in the ratio of mature to polychromatic erythrocytes, compared to the vehicle control, were seen at the 48 hour sampling time for both male and female animals from the high-dose group.
- Conclusions:
- Interpretation of results (migrated information): negative
In a valid guideline study, no statistically significant increase in the incidence of micronucleated PCE's over the control value was observed at any dose-level. Slight increases in the ratio of mature to polychromatic erythrocytes, compared to the vehicle control, were seen at the 48 hour sampling time for both male and female animals from the high-dose group. The substance was negative for genotoxicity in this test. - Executive summary:
The ability of n-butyl methacrylate to cause chromosomal damagein vivowas investigated in a micronucleus OECD 474 test. Dose-levels for treatment were selected on the basis of a preliminary toxicity test. Male and female Swiss CD-1 mice were dosed once intraperitoneally with vehicle only, corn oil, 2000, 1000 and 500 mg/kg bw n-butyl methacrylate and the positive control Mitomycin-C. Five animals per sex from each group were sacrificed at the 24 hour sampling time. The additional animals were sacrificed at the 48 hour sampling time. Following treatment with n-butyl methacrylate, no statistically significant increase in the incidence of micronucleated PCE's over the control value was observed at any dose-level. Slight increases in the ratio of mature to polychromatic erythrocytes, compared to the vehicle control, were seen at the 48 hour sampling time for both male and female animals from the high-dose group, indicating that the test substance exerted a mild toxic effect on the bone marrow cells. Following treatment with the positive control Mitomycin-C, statistically significant increases in the incidence of micronucleated PCE's over the control values were seen in the positive control group indicating the correct functioning of the test system. It is concluded that n-butyl methacrylate administered intraperitoneally at dose-levels of 2000, 1000 and 500 mg/kg bodyweight to both male and female animals, does not induce micronuclei in the polychromatic erythrocytes of treated mice, under the reported experimental conditions.
Referenceopen allclose all
The substance has been administered by gavage as a solution in olive oil in 3 single doses ranging from 1130 mg/kg to 4520 mg/kg (0.5 LD50) 24 h prior to preparation of the bone marrow. A separate group of 5 animals was administered 4 doses of 1130 mg/kg 96, 72, 48 and 24 h prior to preparation. Olive oil (25 ml/kg) was used as the solvent control and mitomycin C (3 mg/kg, i.p.) as the positive control. 2000 erythrocytes were evaluated per animal (12000/10000 per dose). No increase in micronucleated polychromatic erythrocytes was observed at any dose, while an induction of micronuclei was seen in the positive control. MMA was not mutagenic in vivo under test conditions.
Following are the results for the male and female animals combined:
Incidence of NCE/PCE
Dose micronucleated Mean
Treatment Level PCE Ratio
(mg/kg) Mean S.E.
-----------------------------------------------------------
24 hr. Sampling time
-----------------------------------------------------------
Vehicle (corn oil)
10 0.5 0.2 1.12
-----------------------------------------------------------
(ml/kg)
n-butyl methacrylate
500 0.6 0.2 1.19
n-butyl methacrylate
1000 0.9 0.2 0.93
n-butyl methacrylate
2000 0.6 0.2 1.15
-----------------------------------------------------------
Mitomycin-C 2.0 33.6*** 6.5 1.32
-----------------------------------------------------------
48 hr. Sampling time
----------------------------------------------------------- Vehicle (corn oil)
10 0.8 0.3 1.10
-----------------------------------------------------------
(ml/kg)
n-butyl methacrylate
2000 1.2 0.3 1.48
-----------------------------------------------------------
*** Incidence significantly greater than control value at p < 0.0001
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Mode of Action Analysis / Human Relevance Framework
see additional information
Additional information
Data availability
The alkyl-methacrylate esters have been tested in a series of bacterial and mammalian tests in vitro and in vivo. For EMA screening information is available for all three endpoints. Looking at the EMA studies in isolation, they are not entirely satisfactory for two reasons: On one hand the available information is not completely conclusive because the in vitro chromosome aberration test and the mouse lymphoma tests are weakly positive and on the other hand the available studies are reliable with restrictions because some aspects of the actual mutagenicity test guidelines are not covered to the last detail. This will be addressed below by category read across, based on scenario 6 of the current RAAF guidance (“different compounds have the same type of effect”; ECHA 2017), based on a common mode of action. An analysis of the mode of action is included in the mutagenicity review for methacrylate esters by R. Albertini (2017), which is attached to this endpoint summary. At several points throughout this assessment reference will be made to this review.
Three separate aspects of the data will be analysed separately: 1. The technical completeness of the information available (in the sense of compliance with the test guidelines); 2. the effects assessment and overall conclusion, whether there is concern that EMA would be mutagenic; and 3. whether the mutagenic potential could have been underestimated or misjudged by the approach chosen.
1. Technical completeness of the dataset
The approach taken here is as follows: The available EMA studies are supplemented with studies from the adjacent members of the category of lower alkyl (C1-C8) methacrylates, methyl methacrylate and n-butyl methacrylate, in such a way that the most pertinent and relevant studies were selected from the MMA and n-BMA datasets.
a) Gene Mutation Tests
- Bacterial gene mutation tests
Ester | Type of test | Test system | Doses | Metabolic activation | Result | Reference |
MMA | Similar to OECD 471, Salmonella reverse mutation test, pre-incubation method | S. typh. (strains TA98, TA100, TA1535, TA1537) | 10 – 10,000 µg/plate | Aroclor-induced rat and hamster S9-mix | negative | Zeiger et al., 1987 |
Similar to OECD 471, Salmonella reverse mutation test, pre-incubation method | S. typh. (strains TA97, TA98, TA100, TA102, TA104) | 5 – 25,000 µg/plate | PB-induced rat S9-mix | negative | Schweikl et al., 1994 | |
EMA | Similar to OECD 471, Salmonella reverse mutation test, pre-incubation method | S. typh. (strains TA98, TA100, TA1535, TA1537) | 33 – 10,000 µg/plate | Aroclor-induced rat and hamster S9-mix | negative | Zeiger et al., 1987 |
n-BMA | Similar to OECD 471, Salmonella reverse mutation test, pre-incubation method | S. typh. (strains TA98, TA100, TA1535, TA1537) | 100 – 10,000 µg/plate | Aroclor-induced rat and hamster S9-mix | negative | Zeiger et al., 1987 |
OECD 471/472 Salmonella reverse mutation test, pre-incubation method | S. typh. (strains TA100, TA1535, TA98, TA1537) E. coli WP2 uvr A | 9.8 – 625 µg/plate | PB/5,6-BFa-induced rat S9-mix | negative | Nakajima et al., 1998a |
EMA has been tested in a standardized bacterial mutation test according to an NTP protocol with four S. typhimurium strains TA98, TA100, TA1535 and TA 1537 with and without metabolic activation (Zeiger et al. 1987; rat and hamster-derived liver S9). Technically, this test lacks one of the current guideline strains (E. coli WP2 uvrA, or E. coli WP2 uvrA (pKM101), or S. typhimurium TA102).
As indicated in the table above, reliable bacterial reverse mutation tests with a full complement of strains are available for both adjacent category members. The category read-across is justified based upon a common mode of action (electrophilic reactivity of the double bond in the ester). Differences in reactivity between the alkyl esters are small as evidenced by similar electrophilic reactivity towards glutathione.
For MMA reliable test data are available for eight different bacterial strains, including those recommended in the EC test guideline (Zeiger et al. 1987, Schweikl et al. 1994), for nBMA the recommended complement of strains has been tested (Zeiger et al., 1987; Nakajima et al., 1998a)
All tests have been performed over a relevant dose range in the bacterial reverse mutation test (Ames test) with and without metabolic activation by S9-mix.
- Gene mutation tests in mammalian cells
Ester | Type of test | Test system | Doses | Metabolic activation | Result | Reference |
MMA
| Mouse Lymphoma Assay | Mouse lymphoma cell line L5178Y heterozygous TK+/- | 700 – 2298 µg/ml | none | Weakly +ve at cytotoxic concsb | Moore et al. 1988 |
Mouse Lymphoma Assay | Mouse lymphoma cell line L5178Y heterozygous TK+/- | 125 – 1500 µg/ml | Aroclor-ainduced rat S9-mix | +ve at cytotoxic concsb | NTP, 1986 | |
HPRT Assay | Chinese Hamster lung cell line V79 heterozygous HPRT +/- | 1000, 2000 µg/ml | none | Weakly +ve (see discussion) | Schweikl et al., 1998 | |
EMA | Mouse Lymphoma Assay | Mouse lymphoma cell line L5178Y heterozygous TK+/- | 700 – 2298 µg/ml | none | Weakly +ve at cytotoxic concsb | Moore et al. 1988 |
n-BMA | HPRT Assay | Chinese Hamster lung cell line V79 heterozygous HPRT +/- | 445 – 710 µg/ml (lim. by solubility) | PB/NF-ainduced rat S9-mix | negative | Envigo, 2016 |
a Phenobarbital and beta-Naphthoflavone
b Based on other findings of that study, the authors conclude that this effect is due to clastogenic effects rather than gene mutations.
In mammalian cells, EMA was weakly positive at concentrations of >1000mg/mL in a mouse lymphoma gene mutation assay in vitro in a study consistent with OECD Guideline 476 (Moore et al., 1989). The study is reliable with restrictions as the majority of the test concentrations is clearly above the guideline recommendation of 10 mM (1200 mg/ml). The study has only been performed without metabolic activation. For the majority of the test concentrations the survival is borderline low (10-20 %) and for some it is below the guideline recommendation of 10 %.
The dataset is completed in a weight of evidence approach by category read-across to studies of the adjacent members of the category of lower alkyl (C1-C8) methacrylates, methyl methacrylate and n-butyl methacrylate. Again, only the most pertinent and relevant studies were selected from the MMA and n-BMA datasets.
From the MMA dataset three studies are included in the weight of evidence approach: The mouse lymphoma assay performed by NTP (NTP, 1986a), the Mouse Lymphoma publications by Moore et al (Moore et al., 1988, Moore and Doerr 1990) and an HPRT assay in V79 cells by Schweikl et al. (1998). For MMA, the only complete study from a technical point of view is the NTP study. The other two are used to complement the data from a scientific point of view.
The studies by Moore et al and Schweikl et al are clearly limited in their scope and reliability because most test concentrations are above the recommendations of the test guideline and testing has been performed without metabolic activation only.
One study is read across from the n-BMA dataset. Recently a HPRT assay in the V79 cell line has been performed according to the actual test guideline. The test was performed with and without metabolic activation in a relevant range of concentrations (up to 5 mM/719 µg/ml).
b) Chromosome mutation tests
- in vitro
Ester | Type of test | Test system | Doses | Metabolic activation | Result | Reference |
|
MMA | In vitro chromo-some aberration assay | Chinese hamster ovary (CHO) cell line | 750-5000 µg/ml (7.5-50 mM) | Aroclor-induced rat S9-mix | positivea | Anderson et al., 1990 NTP, 1986a |
|
EMA | In vitro chromo-some aberration assay | Chinese hamster ovary (CHO) cell line | 1000-3000 µg/ml (4.4-26 mM) | Aroclor-induced rat S9-mix | negative | NTP, 2002 |
|
n-BMA | OECD 473, In vitro chromo-some aberration assay | Chinese hamster lung (CHL) cell line | 178 - 1420 µg/ml (1.25-10 mM) | PB/5,6-BFb-induced rat S9-mix | negative | Nakajima et al., 1998b |
a Highest concentrations in test (30-50 mM) are 6-10 fold above current guideline recommendations for non-toxic chemicals. In addition, based on cytotoxicity data in other tests, significant cytotoxicity above 50% would have occurred
b Phenobarbital and beta-Naphthoflavone Based on other findings of that study, the authors conclude that this effect is due to clastogenic effects rather than gene mutations.
EMA has been tested in CHO cells in the presence and absence of metabolic activation (NTP, 2002). The test concentrations are up to the limit of cytotoxicity, but above the current guideline recommendation (5 mg/ml or 10 mM, whichever is the lowest). Apart from the high concentrations the study protocol is comparable to current guideline recommendations with acceptable restrictions.
Although not necessary from a technical perspective, but in order to put the results into perspective in the category, two tests from the adjacent members of the category of lower alkyl (C1-C8) methacrylates, methyl methacrylate and n-butyl methacrylate have been added to the dataset.
In a chromosome aberration assay MMA was tested in the CHO cell line. With S-9 mix, treatment was for 2 h followed by 8 to 10 h recovery. Without S-9 mix, treatment time was 8 hours with 2.0 to 2.5 h recovery. Doses up to 5000 μg/ml were tested. From the data presentation and the general approach of the authors and in vitro cytotoxicity data from other studies it can be assumed that the highest doses tested led to pronounced cytotoxic effects. (Anderson et al., 1990).
n-Butyl methacrylate (n-BMA) was tested in an in vitro chromosomal aberration test in Chinese hamster lung fibroblasts (CHL; Nakajima et al., 1998b). The study was performed following the OECD 473 guideline and GLP. The concentrations were set based on the results of previously conducted cell growth inhibition tests. The test was performed at concentrations of 178, 355, 710 and 1420 µg n-BMA/ml (≈10mM) with treatments of 6, 24 and 48 hours (continuous treatment method) without metabolic activation and at concentrations of 355, 710 and 1420 µg n-BMA/ml for 6 hours (short term treatment) with metabolic activation.
- in vivo
As the in vitro cytogenicity test with EMA is considered to be negative, an in vivo test is technically not required. Nevertheless, for the overall evaluation following the effects assessment reference is made to in vivo studies of the adjacent members of the category of lower alkyl (C1-C8) methacrylates, methyl methacrylate and n-butyl methacrylate.
2. Effects assessment
While the dataset in total is considered complete from a technical point of view there remain two main issues at this point – an analysis of the individual test results per endpoint and the overall conclusion with an analysis of the confidence in the approach taken.
a) Gene Mutation Tests
- Bacterial gene mutation tests
EMA
In a standardized bacterial mutation test according to NTP protocol, EMA was not mutagenic in S. typhimurium strains TA98, TA100, TA1535 and TA 1537 with and without metabolic activation by S9 mix from Aroclor-induced rat and hamster liver (Zeiger et al. 1987). EMA was tested in a dose range of 100 to 10,000 g/plate by the preincubation protocol.
Formally, test data in E. coli WP2 uvrA, or E. coli WP2 uvrA (pKM101), or S. typhimurium TA102 are missing according to the current test guideline. Full test data are available for the category neighbours.
Category neighbours (MMA and nBMA)
MMA: In a standardized test according to the NTP protocol, methyl methacrylate was not mutagenic in S. typhimurium strains TA98, TA100, TA1535 and TA 1537 with and without metabolic activation (Zeiger et al. 1987). Additional S. typhimurium strains have been tested by Schweikl et al. (1994; TA97, TA98, TA100, TA102, TA104) including those, which are sensitive for crosslinking and oxidising agents. Methyl methacrylate was not mutagenic in bacteria.
nBMA: The potential of n-butyl methacrylate to induce reverse mutation in Salmonella typhimurium (strains: TA 1535, TA 1537, TA 98, and TA 100) and in Escherichia coli WP2 uvrA was evaluated in accordance with the international guidelines (OECD 471, Commission Directive No. B13/14) in compliance with GLP (Nakajima et al., 1998a). n-Butyl methacrylate was tested in two independent experiments by the preincubation method, with and without a metabolic activation system, both performed in a range of 7 or 8 doses from 9.77 to 1250 µg/plate. Under these experimental conditions, n-butyl methacrylate did not show any mutagenic activity in the bacterial reverse mutation test with Salmonella typhimurium and Escherichia coli.
In addition, an extensive, tabular overview of over 40 bacterial reverse mutation test data with 27 different methacrylates has been attached to this endpoint summary. In the absence of special reactivity in the alcohol side chain methacrylic acid and the methacrylate esters - all sharing the same reactive principle, the double bond in the acid part of the molecule - did not show mutagenicity in bacteria.
Primary metabolites (methacrylic acid and ethanol)
Neither methacrylic acid nor ethanol are regarded as mutagens in bacterial gene mutation tests.
- Gene mutation tests in mammalian cells
EMA
In mammalian cells, EMA was weakly positive at concentrations of >1000 mg/mL (> 8 mM) in a mouse lymphoma gene mutation assay in vitro in a study consistent with OECD Guideline 476 (Moore et al., 1989). As indicated above, this mutagenicity was associated with pronounced toxicity. Primarily small-colony mutants were observed (62-85 %), which indicates that chromosome aberrations (deletions) rather than gene mutations were the reason for the mutant colonies (Moore and Doerr, 1990). The test includes only data without metabolic activation. Full test data are available for the category neighbours.
Category neighbours (MMA and nBMA)
MMA: The dataset is completed in a weight of evidence approach by category read-across to studies of the adjacent members of the category of lower alkyl (C1-C8) methacrylates, methyl methacrylate and n-butyl methacrylate. Again, only the most pertinent and relevant studies were selected from the MMA and n-BMA datasets. From the MMA dataset three studies are included in the weight of evidence approach: The MLTK study by NTP (NTP, 1986a), the two MLTK publications by Moore et al (Moore et al., 1988, Moore and Doerr 1990) and the HPRT assay by Schweikl et al. (1998). In the NTP study MMA was tested with and without metabolic activation Aroclor-induced rat liver S9. The concentration range was 125 µg/ml to 1000 µg/ml without and 125 µg/ml to 1500 µg/ml with metabolic activation, all doses in duplicate or triplicate with independent repeat (solvent: 10 % ethanol). MMA was mutagenic with and without metabolic activation. Positive effects without metabolic activation occurred only at concentrations with high cytotoxicity. The other MLTK study (Moore et al. 1988; Moore and Doerr, 1990) is included here because it addresses colony size as an additional aspect. In this study mouse lymphoma cells were treated with MMA only without metabolic activation in a concentration range between 100 and 3000 µg/ml (10-30 mM). Weak increases in mutagenicity occurred at concentrations above 2000 µg/ml (20 mM) with no clear concentration-effect-relationship (plateau effect with fluctuations). Colony size in that study was reported in the paper of Moore and Doerr (1990) with 69-89 % with only the small colony mutant numbers being increased at higher concentrations. The occurrence of primarily small colonies indicates that chromosome aberrations (deletion of the part of the chromosome bearing the TK locus) are the primary cause of the TK mutations observed. The third study, the HPRT test in V79 Chinese hamster lung cells, was performed at 10 and 20 mM (1000 and 2000 µg/ml without metabolic activation only). While no effect occurred at the lower concentration a weak increase in HPRT mutants was observed at the higher concentration at high but acceptable cytotoxicity (49 % survival).
nBMA was tested in HPRT test in Chinese hamster lung fibroblasts (V79; Envigo, 2016). The study was performed following the OECD 476 and corresponding EC B.17 guidelines and under GLP. The concentrations were set based on the results of previously conducted cell growth inhibition tests. Up to the highest concentration of 355 µg/ml (≈2.5 mM; without metabolic activation) and 710 µg n-BMA/ml (≈5 mM; with metabolic activation; rat liver S9) with a treatment period of 4 hours there was no relevant increase in gene mutations. nBMA is considered to be non-mutagenic under the conditions of the test.
Primary metabolites (methacrylic acid and ethanol)
Neither methacrylic acid nor ethanol are regarded as mutagens in mammalian cell mutation tests.
b) Chromosome mutation tests
- in vitro
EMA
EMA has been tested in CHO cells in the presence and absence of metabolic activation (NPT, 2002; performed in 1986, reported in 2002). Under the conditions of the test and up to the highest test concentration (3000 µg/ml; 26 mM) there was no increase in chromosome aberrations. With cytotoxic effects observed at higher concentrations the test is up to the limit of cytotoxicity, but also above the current guideline recommendation for the selection of the highest concentration in chromosome aberrations tests (5 mg/ml or 10 mM, whichever is the lowest). Nevertheless, in this chromosome aberration test EMA is non-mutagenic.
In another test in mouse lymphoma cells, which are used for the gene mutation assay at the TK locus, EMA was weakly positive at concentrations of >1000 mg/mL (> 8 mM; performedonlywithout metabolic activation). This mutagenicity was associated with pronounced cytotoxicity. In the TK test, primarily small-colony mutants were observed, which also indicates that chromosome aberrations (deletions) rather than gene mutations were the reason for the mutant colonies in the TK test (Moore et al. 1988; Moore and Doerr, 1990).
Category neighbours (MMA and nBMA)
MMA was tested in a chromosome aberration test in the Chinese hamster ovary (CHO) cell line (Anderson et al., 1990). Cells were treated with and without metabolic activation (Aroclor-induced rat S9-mix) in a range of concentrations between 10 and 3000 µg/ml (0.1-30 mM) without metabolic activation) and 160 and 5000 µg/ml (1.6-50 mM) with metabolic activation. Recording of cytotoxicity was mentioned in the publication but is not documented. Without metabolic activation there are two trials, one positive at the high dose (1600 µg/ml; 16 mM) and the second statistically significant at 1600 and 3000 µg/ml. The aberration rate in this case (5/100 cells) is within the range of published control values (0 – 5 aberrations/100 cells). Hence, the result without metabolic activation in this case would be regarded as weakly positive or equivocal. With metabolic activation the test was positive at the highest concentration (5000 µg/ml, 50 mM).
nBMA was tested in an in vitro chromosomal aberration test in Chinese hamster lung fibroblasts (CHL; Nakajima et al., 1998b). The study was performed following the OECD 473 guideline and GLP. The concentrations were set based on the results of previously conducted cell growth inhibition tests. Up to the highest concentration of 710 µg/ml (≈5 mM; without metabolic activation) and 1420 µg n-BMA/ml (≈10 mM; with metabolic activation) with treatments of 6, 24 and 48 hours (continuous treatment method) without metabolic activation and for 6 hours (short term treatment) with metabolic activation there was no relevant increase in gene mutations. nBMA is considered to be non-mutagenic under the conditions of the test.
In addition, an extensive, tabular overview of over 60 mutation test data with 31 different methacrylates has been attached to this endpoint summary. With the exception of two methacrylates wit complex alcohols (trimethylolpropane and trimethoxysilylpropanol) induction of chromosome aberrations in vitro was only observed in relatively small methacrylate esters of low or moderate polarity.
Primary metabolites (methacrylic acid and ethanol)
Neither methacrylic acid nor ethanol are regarded as mutagens in mammalian cytogenicity tests.
- in vivo
EMA
There are no in vivo data for EMA.
Category neighbours (MMA and nBMA)
MMA: A dominant lethal assay is available for MMA (Anderson and Hodge, 1976). In this study groups of 20 male CD-1 mice were exposed via inhalation to MMA at 100, 1000, or 9000 ppm (416, 4160 and 37440 mg/m3) for 6 h/day for 5 days. Each male was subsequently mated with 2 different unexposed female mice weekly over a period of 8 weeks). Specific data on toxicity were not given, however, in the highest dose group 6/20 males died. MMA did not induce dominant lethal mutations as indicated by no adverse effect on total implants and early or late post-implantation death in the offspring of treated males compared to controls.
Two chromosomal aberration tests were conducted by Anderson et al. (1976, 1979) investigating the effect of inhalation exposure to methyl methacrylate for doses ranging from ca. 0.4 to 36.5 mg/L (100 to 9000 ppm). In both tests acute exposure was for 2 h (sampling 24 h after treatment) and subacute exposure for 5 h a day on 5 consecutive days (sampling 24 h after last treatment). Data on toxicity were not given. Group sizes varied from 2 to 9; as far as possible 50 metaphases were analysed per animal. The first study was negative for chromosomal aberration frequencies when - as usual - gaps were excluded. Including gaps and combining two acute experiments conducted independently some increases in aberration frequency were statistically significant. ” This is also due to a particularly low control rate in this experimental segment. Compared to other, almost twofold higher control values in other segments of the report, this finding appears to be of little biological importance. Further from the MMA ESR (ECB, 2002): “In the second study frequencies of chromosomal aberrations excluding gaps were not given. Including gaps increases were recorded at some experimental entries. Furthermore, combined data on chromosomal aberration frequencies exclusively gaps from both studies were given, then weak increases were obtained for 400 and 700 ppm in the acute study (not for 100, 1,000 or 9,000 ppm) and 9,000 ppm in the subacute study. Both studies suffer from inadequate description; esp. the second study demonstrates severe methodological problems, e. g., analysis of 50 metaphases was not possible for 10 out of 27 animals in the acute and 10 out 26 in the subacute test. Altogether, the studies do not give a unanimous picture.
Hachitani et al. (1981) (other sources translate the name as Hachitani) reported on a negative bone marrow micronucleus assay with mice. In an acute test methyl methacrylate was given by gavage in doses ranging from 1,130 to 4,520 mg/kg, in a subacute assay daily doses of 1,130 mg/kg were given on 4 consecutive days. All groups consisted of 6 animals; sampling was done 24 h after (last) administration. There was no increase in the frequency of micronucleated polychromatic erythrocytes. The percentage of reticulocytes from all bone marrow cells was not affected data on general toxicity were not given.
N-BMA has been assessed in vivo in a mouse bone marrow micronucleus test (Cilliutti, 1999). The test substance has been dosed up to the highest guideline dose of 2000 mg/kg via the intraperitoneal route. No toxicity was seen at the low and medium doses (500 and 1000 mg/kg) while slight toxicity was demonstrated at the high dose by a slight reduction in the PCE/NCE coefficient. As no increase in micronuclei was observed, n-BMA is regarded as non-mutagenic under the test conditions
Primary metabolites (methacrylic acid and ethanol)
Neither methacrylic acid nor ethanol are regarded as mutagens in vivo.
c) Tests for Aneugenic effects
Although there are no studies on EMA, neither of the two chromosome aberration tests in vitro on n-BMA and 2-EHMA (Nakajima et al., 1998; Ohta et al., 1998) or the micronucleus tests in vivo with n-BMA and i-BMA (Völkner 1989, Ciliutti, 1999) indicated that the category of methacrylate esters has aneugenic potential.
3. Conclusion and confidence in the approach taken.
This discussion refers to four data elements: test data on EMA itself, the read-across information from the category of lower alkyl (C1-C8) methacrylates (focusing on the two immediate neighbours MMA and nBMA) and, most important, on the comprehensive review on reactivity, genotoxicity and mutagenicity data of the lower alkyl methacrylates by Prof. Richard Albertini in 2017.
The read-across approach is based on scenario 6 of the current RAAF (Different compounds have the same type of effect) in based on a common mode of action. An analysis of the mode of action is included in the mutagenicity review for methacrylate esters by R. Albertini (2017), which is attached to this endpoint summary. The reactive group common to all methacrylates is the double bond of the methacrylic part of the molecule, which is electrophilic and may take place in Michael addition reactions.
For each individual endpoint there is a reliable study available. If the EMA study has technical weaknesses, at least one reliable read-across study is available for the adjacent esters in the category. If there are positive effects in vivo there are corresponding, conclusive studies in vivo, which are negative.
Gene mutations in bacteria: The EMA study is reliable, but lacks one standard strain. Corresponding studies for MMA and nBMA are complete – and equally negative. Based on the common mode of action, the Albertini review, the category data and the comprehensive methacrylate overview it is evident, that an additional bacterial reverse mutation test is not necessary. EMA is regarded as non-mutagenic in bacteria. This conclusion, partly based on category read-across, is taken with high confidence.
Gene mutations in mammalian cells: The EMA study is reliable with significant restrictions (no data with metabolic activation). Increased mutation rates, also in the read-across chemical MMA correlate with small colony mutants and chromosome aberrations. Tests in the more robust HPRT test are negative in summary. With the corresponding studies for MMA and nBMA the dataset is complete. Based on the common mode of action, the Albertini review and the category data, it is evident, that an additional gene mutation test in mammalian cells is not necessary. Regarding gene mutations, EMA is regarded as non-mutagenic in mammalian cells. Positive findings are related to chromosome breakage. This conclusion, partly based on category read-across, is taken with high confidence.
Chromosome mutations in mammalian cells: The EMA key study is negative, but a supporting study is positive. Throughout the lower alkyl methacrylate category, positive findings in chromosome aberration tests are associated with high toxicity and very high concentrations (above the current guideline recommendation. Performed under currently prevalent test conditions, practically all of these tests – at correspondingly lower concentrations - would lead to a negative test result today. Based on the common mode of action, the Albertini review , the category data and the comprehensive methacrylate overview, it is evident, that an additional chromosome mutation test in mammalian cells is not necessary. Regarding gene mutations, EMA is regarded as non-mutagenic in mammalian cells. This conclusion, partly based on category read-across, is taken with high confidence and it is consistent with the result of a RAC discussion regarding MMA in 2016, based on almost the same database.
Genetic toxicity in vivo: all relevant studies from MMA and nBMA as nearest neighbours in the category indicate an absence of mutagenic potential in vivo for these substances. The same is assessed for EMA with a high level of confidence as also the primary metabolites are not mutagenic in vivo.
Overall, the results of the available, fully valid test data indicate, covering all relevant endpoints, that the members of the category are not mutagenic or genotoxic. This is consistent with a much more comprehensive review of methacrylate data by Albertini (2017) and all previous national and international reviews on EMA. Additional guideline tests with EMA would investigate the mutagenic potential of EMA in non-cytotoxic concentrations which are significantly lower than the currently available studies. Hence, an additional risk from not performing new studies is not expected with a high level of certainty.
Justification for classification or non-classification
An overall assessment based on the aforementioned three assessment elements (i.e. test data on EMA itself, the read-across information from the category of lower alkyl (C1-C8) methacrylates (focusing on the two immediate neighbours MMA and nBMA) and, most important, on the comprehensive review on reactivity, genotoxicity and mutagenicity data of the lower alkyl methacrylates by Prof. Richard Albertini in 2017) leads to the conclusion that EMA is not mutagenic.
Hence, no classification is warranted for EMA.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1